Back to News
Market Impact: 0.35
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Wave reported that WVE-007 clinical data showed fat loss without muscle loss and support potential dosing of 1-2 times annually. In preclinical testing, Wave's INHBE GalNAc-siRNA combined with a GLP-1 treatment doubled weight loss versus GLP-1 alone, supporting the obesity-treatment candidate's differentiation potential.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
WVE0.82
More News
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- These funds tout hefty income tied to the tech trade – if you’re willing to deal with the complexity
- Street Calls of The Week
- Meta’s $25 Billion Bond Sale Highlights Shifting Landscape for Tech Debt
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Coffee giant Dutch Bros made all of its executives, including the CEO, do a two-week bootcamp where they learned how to pour drinks and run stores